* 0.05. 6-, and 12-month-old WT, mice. (A and B) Confocal images Mouse monoclonal to cMyc Tag. Myc Tag antibody is part of the Tag series of antibodies, the best quality in the research. The immunogen of cMyc Tag antibody is a synthetic peptide corresponding to residues 410419 of the human p62 cmyc protein conjugated to KLH. cMyc Tag antibody is suitable for detecting the expression level of cMyc or its fusion proteins where the cMyc Tag is terminal or internal. of CD31+ microvessels (A) and quantification of microvascular density (B) in the hippocampus of 6- and 12-month-old WT, Adamts13?/?, = 6). Scale bar, 50 m. Relevant data values are included in S2 Data. Values are mean SD. * 0.05. ADAMTS13, a disintegrin and metalloprotease with thrombospondin type I motif, member 13; CD31, platelet endothelial cell adhesion molecule-1; WT, wild type.(PDF) pbio.3000313.s005.pdf (279K) GUID:?FEFBCA84-6986-45B2-9751-4E751D629EAE S6 Fig: ADAMTS13 deficiency does not affect A processing and the microvascular levels of A influx transporter RAGE. Immunoblot analysis of full-length APP, CTFs, and BACE1 in brain tissue and RAGE in isolated brain microvessels of WT, = 5). Relevant data values are included in S2 Data. Values are mean SD. * 0.05. ADAMTS13, a disintegrin and metalloprotease with thrombospondin type I motif, member 13; APP, amyloid precursor protein; A, amyloid-; BACE1, -secretase; CTF, C-terminal fragment; NS, not significant; RAGE, receptor for advanced glycation end products; WT, wild type.(PDF) pbio.3000313.s006.pdf (75K) GUID:?22682879-FA9E-4C19-90C6-07180F0D7DCA S7 Fig: Overexpression of LRP1 in the hippocampus of APPPS1CAdamts13?/? mice using Adv-mLRP1. (A) Representative immunoblotting analysis of LRP-555 and mLRP1 in the Hpc of 0.05. WT, wild type.(PDF) pbio.3000313.s008.pdf (58K) GUID:?4EBC83DA-A8E3-4B70-825A-6BD3881E3E81 S9 Fig: ADAMTS13 deficiency does not result in A deposition and synaptic dysfunction in young mice. (A) Representative micrographs of amyloid plaques labeled with antibody against A in 2-month-old and and MCH-1 antagonist 1 = 6). Relevant data values are included in S2 Data. (D) Representative images of Golgi-stained dendritic spines from the hippocampal CA1 region of 2-month-old WT, = 3). (F) Representative recordings of mEPSCs in hippocampal CA1 neurons from 2-month-old WT, = 9 to 10 cells from 3 mice. Relevant data values are MCH-1 antagonist 1 included in S2 Data. Values are mean SD. ADAMTS13, a disintegrin and metalloprotease with thrombospondin type I motif, member 13; A, amyloid-; CA1, field CA1 of hippocampus; mEPSC, miniature excitatory postsynaptic current; NS, not significant; WT, wild type.(PDF) pbio.3000313.s009.pdf (597K) GUID:?3694CBD1-DFF4-4C79-9CF8-B48ACAD791D8 S10 Fig: ADAMTS13 adeno-associated virus treatment reduces A deposition in mice. (A MCH-1 antagonist 1 and B) Representative micrographs of amyloid plaques labeled with antibody against A (A) and ThS (B) from the cortex and hippocampus of 12-month-old treated with AAV8-ADAMTS13 or control viruses. Scale bar, 100 m. AAV8, adeno-associated virus serotype 8; ADAMTS13, a disintegrin and metalloprotease with thrombospondin type I motif, member 13; A, amyloid-; ThS, thioflavin S.(PDF) pbio.3000313.s010.pdf (293K) GUID:?AF2CE2E7-051A-479C-B42D-D5937907EDCC S11 Fig: Effects of MCH-1 antagonist 1 rADAMTS13 MCH-1 antagonist 1 on A42 uptake and clearance in astrocytes. (A) Internalization levels of A42 were analyzed by flow cytometry in vehicle- and rADAMTS13-treated astrocytes after incubation with FAM-A42 for 30, 60, and 120 minutes (= 3). (B) Astrocytes were incubated with FAM-A42 for 2 hours, washed, and then incubated FAM-A42Cfree medium for 2 hours in the presence or absence of rADAMTS13. The residual FAM-A42 was measured by ELISA (= 3). Relevant data values are included in S2 Data. A, amyloid-; FAM-A42, A1C42 labeled with 5(6)-carboxyfluorescein; rADAMTS13, recombinant ADAMTS13.(PDF) pbio.3000313.s011.pdf (32K) GUID:?65F7D218-8583-497F-A37B-68D58EF91100 S12 Fig: ADAMTS13 AAV treatment restores cognitive function in mice. (ACB) Number of platform crossings (A) and time spent in the target quadrant in probe trial (B) of the MWM test. (C and D) Total distance traveled (C) and number of rearing (D) in the open-field test in 12-month-old treated with AAV8-ADAMTS13 or control viruses. Relevant data values are included in S2 Data. Values are mean SD. = 13 to 15 per group; * 0.05. AAV8, adeno-associated virus serotype 8; ADAMTS13, a disintegrin and metalloprotease with thrombospondin type I motif, member 13; MWM, Morris Water Maze.(PDF) pbio.3000313.s012.pdf (46K) GUID:?D27A998D-6FE0-4946-86DE-8CC2710EA60E S1 Text: A detailed description of methods and materials. (DOC) pbio.3000313.s013.doc (136K) GUID:?E2D9E1BB-7703-4D52-8E59-867B6DDC5AB7 S1 Data: Underlying data for the following Figs ?Figs1A,1A, 1B, 1D, ?,2C,2C, 2D, 2F, 2G, 2H, 3C, 3D, 3F, 4A, 4B, 4D, 4E, 4G, 4H, 4J, 4K, 4L, 4M, 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5J, 5K, 6D, 6E, 6G, 6I, 6K, 7A, 7B, 7C, 7D, 7F, 7H, 7I, 7J, 7K, 7L, 7O and 7P. (XLSX) pbio.3000313.s014.xlsx (93K) GUID:?94CD33D7-FEEC-4C35-9751-F2EF6DF3D092 S2 Data: Underlying data for the following S2A, S2C, S3A, S3C, S3D, S3E, S3F, S5B, S6A, S8A, S9B, S9C, S9E, S9G, S9H, S11A, S11B, S12A, S12B, S12C and S12D Figs..